80 results
Page 3 of 4
8-K
EX-99.1
34m0 xs0sg
15 Oct 20
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
4:47pm
8-K
prrxl25e2n6h5ei49
15 Oct 20
Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial
4:47pm
8-K
susxcb0vuw82agl95 5s
29 May 20
Regulation FD Disclosure
7:42am
8-K
EX-99.1
u1nzl
29 May 20
Regulation FD Disclosure
7:42am
8-K
EX-99.1
okfasge zg9o30g
14 May 20
Adaptimmune Reports Q1 Financial Results
7:37am
8-K
hcmy8d ayd244lfudoj4
12 May 20
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting
10:54am
8-K
EX-99.1
zztcxm2mow1 gcr4
12 May 20
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting
10:54am
8-K
EX-99.1
rj3ptun
29 Apr 20
Other Events
8:06am
424B5
0en81lflk8kdc7nu4ku
22 Jan 20
Prospectus supplement for primary offering
5:31pm
424B5
22am5op
21 Jan 20
Prospectus supplement for primary offering
5:21pm
8-K
6111 q2gni
30 Sep 19
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing
8:59am
8-K
EX-99.1
b34q1n6xfs78
30 Sep 19
Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing
8:59am
8-K
EX-99.1
0rwqk 6hi1y7dji8
6 May 19
Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors
7:08am
8-K
soctqw8 w3
2 May 19
Other Events
7:10am
8-K
EX-99.1
6z8lq3pfm9qx
2 May 19
Other Events
7:10am